FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2402959096> ?p ?o ?g. }

• W2402959096 endingPage "E60" @default.
• W2402959096 startingPage "E45" @default.
• W2402959096 abstract "Background: Low back pain with or without radiculopathy is an important cause of disability and economic expenditure. However, many patients are not meeting optimal pain control through existing treatments. Recent studies have linked nerve growth factor (NGF) and the pathophysiology of persistent pain. Anti-NGF could be an alternative drug treatment for low back pain. Objective: Systematically review the efficacy and safety of anti-NGF in the treatment of low back pain. Methods: A systematic review of the literature with no language, date or publication status restriction, using Medline, EMBASE, Cochrane Library, and the clinicaltrials.gov database. Additional literature was retrieved by conferring with experts in the field or reviewing bibliographies and annals of meetings and congresses. Search terms included “monoclonal antibodies,” “nerve growth factor,” “anti-ngf,” “fulranumab,” “tanezumab,” “sciatica,” “back pain,” and “spine.” Study Design: Inclusion criteria were observational studies with safety as an outcome and randomized or nonrandomized controlled trials studying the efficacy and/or the safety of antiNGF drugs on low back pain. Exclusion criteria included patients with autoimmune conditions or osteoporosis. Studies were assessed independently by 2 authors regarding inclusion/exclusion criteria, risk of bias, clinical relevance, and quality of evidence (GRADE approach). Results: 1,168 studies were retrieved. After excluding duplicates and applying the inclusion/ exclusion criteria, 4 RCTs remained (n = 2,109): 2 for tanezumab, one for REGN475, and one for fulranumab. Only the tanezumab studies showed any significant difference over placebo (n = 1,563) for both pain relief and functional improvement. Conclusions: There is very low evidence that systemically administered anti-NGF therapy has a small positive effect compared to placebo for both pain relief (standarized mean difference [SMD] = -0.29, 95% confidence interval [CI] -0.58 to 0.00) and functional improvement (SMD = -0.21, 95%CI -0.37 to -0.05 ) of low back pain. There was low evidence of adverse effects (AEs) compared to placebo and low evidence of neurological AEs than placebo (relative risk = 1.93, 95%CI 1.41 to 2.64).Tanezumab, as a specific anti-NGF treatment, showed low evidence of a small to moderate effect for pain relief of low back pain (SMD = -0.44, 95%CI -0.81 to -0.07); and low evidence of a small effect for functional improvement (SMD = -0.26, 95%CI -0.40 to -0.12) with systemic administration, although not clinically significant. Tanezumab and anti-NGFs overall had, respectively, moderate and low evidence of overall AEs and serious AEs and a higher risk of developing neurological AEs when compared with placebo. Although anti-NGF, specifically tanezumab, showed a low-to-moderate effect on pain relief and functional improvement, it cannot be recommended for low back pain treatment. Without more research on the pathophysiology of anti-NGFs and adverse effects, its use is not safe in the overall population. However, as corroborated by the US Food and Drug Administration, this meta-analysis underscores a role for greater insight into anti-NGF therapy for painful conditions that are refractory to current drugs, such as oncologic pain, chronic pancreatitis, and phantom-limb pain. Given the pathophysiology of axial pain involving inflammatory mediators and the adverse effects of systemic anti-NGF use, consideration of local therapies may warrant further exploration. Key Words: back pain, anti-ngf, spine, sciatica, nerve growth factor, radiculopathy, treatment" @default.
• W2402959096 created "2016-06-24" @default.
• W2402959096 creator A5001659378 @default.
• W2402959096 creator A5005084710 @default.
• W2402959096 creator A5009857403 @default.
• W2402959096 creator A5029723062 @default.
• W2402959096 creator A5038751610 @default.
• W2402959096 creator A5038855612 @default.
• W2402959096 creator A5073053202 @default.
• W2402959096 creator A5078032356 @default.
• W2402959096 creator A5082847864 @default.
• W2402959096 date "2014-01-14" @default.
• W2402959096 modified "2023-10-12" @default.
• W2402959096 title "Anti-Nerve Growth Factor in the Treatment of Low Back Pain and Radiculopathy: A Systematic Review and a Meta-Analysis" @default.
• W2402959096 doi "https://doi.org/10.36076/ppj.2014/17/e45" @default.
• W2402959096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24452657" @default.
• W2402959096 hasPublicationYear "2014" @default.
• W2402959096 type Work @default.
• W2402959096 sameAs 2402959096 @default.
• W2402959096 citedByCount "20" @default.
• W2402959096 countsByYear W24029590962014 @default.
• W2402959096 countsByYear W24029590962015 @default.
• W2402959096 countsByYear W24029590962016 @default.
• W2402959096 countsByYear W24029590962017 @default.
• W2402959096 countsByYear W24029590962018 @default.
• W2402959096 countsByYear W24029590962020 @default.
• W2402959096 countsByYear W24029590962021 @default.
• W2402959096 countsByYear W24029590962022 @default.
• W2402959096 crossrefType "journal-article" @default.
• W2402959096 hasAuthorship W2402959096A5001659378 @default.
• W2402959096 hasAuthorship W2402959096A5005084710 @default.
• W2402959096 hasAuthorship W2402959096A5009857403 @default.
• W2402959096 hasAuthorship W2402959096A5029723062 @default.
• W2402959096 hasAuthorship W2402959096A5038751610 @default.
• W2402959096 hasAuthorship W2402959096A5038855612 @default.
• W2402959096 hasAuthorship W2402959096A5073053202 @default.
• W2402959096 hasAuthorship W2402959096A5078032356 @default.
• W2402959096 hasAuthorship W2402959096A5082847864 @default.
• W2402959096 hasBestOaLocation W24029590961 @default.
• W2402959096 hasConcept C126322002 @default.
• W2402959096 hasConcept C142724271 @default.
• W2402959096 hasConcept C168563851 @default.
• W2402959096 hasConcept C17744445 @default.
• W2402959096 hasConcept C1862650 @default.
• W2402959096 hasConcept C189708586 @default.
• W2402959096 hasConcept C199539241 @default.
• W2402959096 hasConcept C204787440 @default.
• W2402959096 hasConcept C27081682 @default.
• W2402959096 hasConcept C2776478404 @default.
• W2402959096 hasConcept C2776501849 @default.
• W2402959096 hasConcept C2776698514 @default.
• W2402959096 hasConcept C2777596629 @default.
• W2402959096 hasConcept C2779473830 @default.
• W2402959096 hasConcept C2780907711 @default.
• W2402959096 hasConcept C71924100 @default.
• W2402959096 hasConcept C95190672 @default.
• W2402959096 hasConceptScore W2402959096C126322002 @default.
• W2402959096 hasConceptScore W2402959096C142724271 @default.
• W2402959096 hasConceptScore W2402959096C168563851 @default.
• W2402959096 hasConceptScore W2402959096C17744445 @default.
• W2402959096 hasConceptScore W2402959096C1862650 @default.
• W2402959096 hasConceptScore W2402959096C189708586 @default.
• W2402959096 hasConceptScore W2402959096C199539241 @default.
• W2402959096 hasConceptScore W2402959096C204787440 @default.
• W2402959096 hasConceptScore W2402959096C27081682 @default.
• W2402959096 hasConceptScore W2402959096C2776478404 @default.
• W2402959096 hasConceptScore W2402959096C2776501849 @default.
• W2402959096 hasConceptScore W2402959096C2776698514 @default.
• W2402959096 hasConceptScore W2402959096C2777596629 @default.
• W2402959096 hasConceptScore W2402959096C2779473830 @default.
• W2402959096 hasConceptScore W2402959096C2780907711 @default.
• W2402959096 hasConceptScore W2402959096C71924100 @default.
• W2402959096 hasConceptScore W2402959096C95190672 @default.
• W2402959096 hasIssue "1;17" @default.
• W2402959096 hasLocation W24029590961 @default.
• W2402959096 hasLocation W24029590962 @default.
• W2402959096 hasOpenAccess W2402959096 @default.
• W2402959096 hasPrimaryLocation W24029590961 @default.
• W2402959096 hasRelatedWork W1971070760 @default.
• W2402959096 hasRelatedWork W2069264694 @default.
• W2402959096 hasRelatedWork W2088019836 @default.
• W2402959096 hasRelatedWork W2402959096 @default.
• W2402959096 hasRelatedWork W2415244915 @default.
• W2402959096 hasRelatedWork W2526435360 @default.
• W2402959096 hasRelatedWork W2892489767 @default.
• W2402959096 hasRelatedWork W3029323012 @default.
• W2402959096 hasRelatedWork W3102826061 @default.
• W2402959096 hasRelatedWork W4286992872 @default.
• W2402959096 hasVolume "17;1" @default.
• W2402959096 isParatext "false" @default.
• W2402959096 isRetracted "false" @default.
• W2402959096 magId "2402959096" @default.
• W2402959096 workType "article" @default.